Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Replicate Design in a Two-treatment, Four-period, Two-sequence Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 29 Jun 2017 Status changed from recruiting to completed.
- 18 Apr 2017 Planned End Date changed from 1 Jul 2017 to 20 Jun 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 16 Jun 2017.